CG Oncology (CGON) Cash from Investing Activities (2023 - 2026)

CG Oncology has reported Cash from Investing Activities for 4 years, with the latest figure at -$334.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 79.28% year-over-year to -$334.8 million; the trailing twelve-month figure through Mar 2026 stood at -$393.9 million (down 118.72% YoY), and the FY2025 full-year result was -$245.8 million, up 18.27% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$334.8 million, down from -$75.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $103.4 million in Q2 2023, with the low at -$334.8 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$77.1 million across 4 years, with a median of -$36.2 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 119.83% — and 2025, when it plunged 792.39%.
• CG Oncology's Cash from Investing Activities stood at $15.5 million in 2023, then slipped by 29.8% to $10.9 million in 2024, then sank by 792.39% to -$75.5 million in 2025, then sank by 343.47% to -$334.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$334.8 million (Q1 2026), -$75.5 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.